Acid blockade by omeprazole or ICI 162846 in a chronic duodenal ulcer model

Agents Actions. 1991 May;33(1-2):161-3. doi: 10.1007/BF01993155.

Abstract

Oral treatment with the H2-antagonist ICI 162,846 or omeprazole for five days inhibited both basal and pentagastrin stimulated acid secretion by 50% or more in mice. Either treatment increased the luminal secretion of histamine in the basal (12-fold) and stimulated (9-fold) states. Mice treated with the H2-antagonist had a 27% reduction (p less than 0.05) in mural histamine in the acid-producing area of the stomach. Mice were treated so as to induce duodenal ulcers (abscopal model) and were then treated with the H2-antagonist ICI 162,846, omeprazole or vehicle, orally for one week. Fewer duodenal ulcers were found in animals receiving drug treatments than in the oral vehicle group. Both the H2-receptor antagonist and the proton pump blocker inhibit acid production; acid blockade by either drug is accompanied by a massive increase in secretion of histamine. This rise was associated with depletion of the gastric histamine store only with H2-receptor blocker. Both means of acid inhibition reduce the formation of ulcers in this model.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphatases / antagonists & inhibitors
  • Animals
  • Duodenal Ulcer / etiology
  • Duodenal Ulcer / physiopathology*
  • Duodenal Ulcer / prevention & control
  • Female
  • Gastric Acid / metabolism*
  • H(+)-K(+)-Exchanging ATPase
  • Histamine / metabolism
  • Histamine H2 Antagonists / pharmacology*
  • Histamine Release / drug effects*
  • Mediastinum / radiation effects
  • Mice
  • Omeprazole / pharmacology*
  • Omeprazole / therapeutic use
  • Pyrazoles / pharmacology*
  • Pyrazoles / therapeutic use

Substances

  • Histamine H2 Antagonists
  • Pyrazoles
  • Histamine
  • ICI 162846
  • Adenosine Triphosphatases
  • H(+)-K(+)-Exchanging ATPase
  • Omeprazole